RedHill Biopharma (RDHL) adds missing MD&A in amended Form 6-K

Rhea-AI Filing Summary

RedHill Biopharma Ltd. filed an amended Form 6-K to correct a prior submission from early September 2025. The company states that the only change is adding Exhibit 99.3, which contains management’s discussion and analysis of first half 2025 financial results.

The previously furnished press release on first half 2025 results (Exhibit 99.1) and the condensed consolidated interim unaudited financial information for the six months ended June 30, 2025 (Exhibit 99.2) are unchanged. The amended Form 6-K is also incorporated by reference into multiple existing Form S-8 and Form F-3 registration statements.

0001553846--12-312025Q2trueRedHill Biopharma Ltd.6-K/A2025-06-3000015538462025-01-012025-06-300001553846rdhl:ExclusiveLicenseAgreementWithHylorisPharmaceuticalsSaMember2025-02-242025-02-240001553846rdhl:ExclusiveLicenseAgreementWithHylorisPharmaceuticalsSaMemberifrs-full:TopOfRangeMember2025-02-240001553846dei:AdrMember2024-08-202024-08-200001553846dei:AdrMember2023-03-232023-03-230001553846dei:AdrMember2023-03-222023-03-2200015538462025-05-132025-05-130001553846rdhl:DirectorsAndChiefExecutiveOfficerMemberrdhl:IfrsRestrictedStockUnitsRsuMember2025-03-310001553846rdhl:EmployeesAndConsultantsMemberrdhl:IfrsRestrictedStockUnitsRsuMember2025-03-260001553846rdhl:MovantikMember2025-01-012025-06-300001553846rdhl:FairValueOfWarrantsMemberifrs-full:TopOfRangeMemberifrs-full:InterestRateMeasurementInputMember2025-06-300001553846rdhl:FairValueOfWarrantsMemberifrs-full:TopOfRangeMemberifrs-full:HistoricalVolatilityForSharesMeasurementInputMember2025-06-300001553846rdhl:FairValueOfWarrantsMemberifrs-full:BottomOfRangeMemberifrs-full:HistoricalVolatilityForSharesMeasurementInputMember2025-06-300001553846ifrs-full:WarrantsMemberifrs-full:AtFairValueMemberrdhl:StandardDeviationMember2025-06-300001553846ifrs-full:WarrantsMemberifrs-full:AtFairValueMemberifrs-full:InterestRateMeasurementInputMember2025-06-300001553846rdhl:FairValueOfWarrantsMemberifrs-full:TopOfRangeMemberifrs-full:InterestRateMeasurementInputMember2024-06-300001553846rdhl:FairValueOfWarrantsMemberifrs-full:TopOfRangeMemberifrs-full:HistoricalVolatilityForSharesMeasurementInputMember2024-06-300001553846rdhl:FairValueOfWarrantsMemberifrs-full:BottomOfRangeMemberifrs-full:InterestRateMeasurementInputMember2024-06-300001553846rdhl:FairValueOfWarrantsMemberifrs-full:BottomOfRangeMemberifrs-full:HistoricalVolatilityForSharesMeasurementInputMember2024-06-300001553846rdhl:GaelanMedicalTradeLlcMembercountry:AE2025-01-012025-06-300001553846rdhl:TaliciaMember2025-01-012025-06-300001553846rdhl:GaelanMedicalTradeLlcMember2025-01-012025-06-300001553846ifrs-full:MajorOrdinaryShareTransactionsMemberrdhl:AlumniMember2025-09-042025-09-040001553846rdhl:AmericanDepositoryShareMember2025-01-012025-06-3000015538462025-05-142025-05-140001553846ifrs-full:MajorOrdinaryShareTransactionsMemberrdhl:AlumniMember2025-09-040001553846rdhl:AmericanDepositoryShareMember2025-06-300001553846rdhl:EmployeesAndConsultantsMemberrdhl:IfrsRestrictedStockUnitsRsuMember2025-03-262025-03-260001553846rdhl:DirectorsAndChiefExecutiveOfficerMemberrdhl:IfrsRestrictedStockUnitsRsuMember2025-03-012025-03-310001553846rdhl:AmericanDepositoryShareMemberrdhl:AlumniMemberifrs-full:TopOfRangeMember2025-06-200001553846rdhl:HylorisPharmaceuticalsSaMemberifrs-full:GoodsOrServicesTransferredOverTimeMember2025-01-012025-06-300001553846rdhl:HylorisPharmaceuticalsSaMemberifrs-full:GoodsOrServicesTransferredAtPointInTimeMember2025-01-012025-06-300001553846rdhl:HylorisPharmaceuticalsSaMember2025-01-012025-06-300001553846ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMemberrdhl:FairValueOfWarrantsMemberifrs-full:Level3OfFairValueHierarchyMember2025-06-300001553846ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMemberrdhl:FairValueOfWarrantsMemberifrs-full:Level3OfFairValueHierarchyMember2024-12-310001553846ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMemberrdhl:FairValueOfWarrantsMemberifrs-full:Level3OfFairValueHierarchyMember2024-06-300001553846ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMemberrdhl:FairValueOfWarrantsMemberifrs-full:Level3OfFairValueHierarchyMember2023-12-310001553846ifrs-full:IssuedCapitalMember2025-01-012025-06-300001553846ifrs-full:AdditionalPaidinCapitalMember2025-01-012025-06-300001553846ifrs-full:IssuedCapitalMember2024-01-012024-06-300001553846ifrs-full:AdditionalPaidinCapitalMember2024-01-012024-06-300001553846ifrs-full:RetainedEarningsMember2025-01-012025-06-300001553846ifrs-full:RetainedEarningsMember2024-01-012024-06-300001553846rdhl:RebatesAndPatientDiscountProgramsMember2025-01-012025-06-300001553846rdhl:ProductReturnsMember2025-01-012025-06-300001553846rdhl:RebatesAndPatientDiscountProgramsMember2024-01-012024-06-300001553846rdhl:ProductReturnsMember2024-01-012024-06-300001553846ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMemberrdhl:FairValueOfWarrantsMemberifrs-full:Level3OfFairValueHierarchyMember2025-01-012025-06-300001553846ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMemberrdhl:FairValueOfWarrantsMemberifrs-full:Level3OfFairValueHierarchyMember2024-01-012024-06-300001553846ifrs-full:RetainedEarningsMember2025-06-300001553846ifrs-full:IssuedCapitalMember2025-06-300001553846ifrs-full:AdditionalPaidinCapitalMember2025-06-300001553846ifrs-full:RetainedEarningsMember2024-12-310001553846ifrs-full:IssuedCapitalMember2024-12-310001553846ifrs-full:AdditionalPaidinCapitalMember2024-12-310001553846ifrs-full:RetainedEarningsMember2024-06-300001553846ifrs-full:IssuedCapitalMember2024-06-300001553846ifrs-full:AdditionalPaidinCapitalMember2024-06-300001553846ifrs-full:RetainedEarningsMember2023-12-310001553846ifrs-full:IssuedCapitalMember2023-12-310001553846ifrs-full:AdditionalPaidinCapitalMember2023-12-310001553846rdhl:RebatesAndPatientDiscountProgramsMember2025-06-300001553846rdhl:ProductReturnsMember2025-06-300001553846rdhl:RebatesAndPatientDiscountProgramsMember2024-12-310001553846rdhl:ProductReturnsMember2024-12-310001553846rdhl:RebatesAndPatientDiscountProgramsMember2024-06-300001553846rdhl:ProductReturnsMember2024-06-300001553846rdhl:RebatesAndPatientDiscountProgramsMember2023-12-310001553846rdhl:ProductReturnsMember2023-12-3100015538462024-06-3000015538462023-12-3100015538462024-01-012024-06-3000015538462025-06-3000015538462024-12-31iso4217:USDxbrli:sharesiso4217:USDxbrli:sharesxbrli:purerdhl:installment

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

​

FORM 6-K/A

​

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

​

For the month of September 2025

Commission File No.:001-35773

​

REDHILL BIOPHARMA LTD.

(Translation of registrant’s name into English)

​

21 Ha’arba’a Street, Tel Aviv, 6473921, Israel

(Address of principal executive offices)

​

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒       Form 40-F ☐

RedHill Biopharma Ltd. is amending its Report on Form 6-K furnished to the U.S. Securities and Exchange Commission on September 5, 2025 (the “Original Form 6-K”) solely to include exhibit 99.3 which was inadvertently not included in the Original Form 6-K. The information contained in the Original Form 6-K otherwise remains unchanged.

Attached hereto and incorporated by reference herein are the following:

Exhibit 99.1: Registrant’s press release entitled “RedHill Biopharma Announces First Half 2025 Financial Results and Operational Highlights”.

Exhibit 99.2: Registrant’s condensed consolidated interim unaudited financial information as of June 30, 2025, and for the six months then ended.

Exhibit 99.3: Registrant’s Management Discussion and Analysis of First Half 2025 Financial Results.

This Form 6-K/A is hereby incorporated by reference into the Company’s Registration Statements on Form S-8 filed with the Securities and Exchange Commission on May 2, 2013 (Registration No. 333-188286), on October 29, 2015 (Registration No. 333-207654), on July 25, 2017 (Registration No. 333-219441), on May 23, 2018 (Registration No. 333-225122), on July 24, 2019 (File No. 333-232776), on March 25, 2021 (File No. 333-254692), on May 3, 2021 (File No. 333-255710), on January 11, 2022 (File No. 333-262099), on June 27, 2022 (File No. 333-265845), on June 29, 2023 (File No. 333-273001), on June 20, 2024 (File No. 333-280327) and on March 25, 2025 (File No. 333-286082), and its Registration Statements on Form F-3 filed with the Securities and Exchange Commission on March 30, 2021 (File No. 333-254848), on August 4, 2023 (File No. 333-273709), on October 13, 2023 (File No. 333-274957), as amended, and on August 9, 2024 (File No. 333-281417).

​

​

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	REDHILL BIOPHARMA LTD.
	(the “Registrant”)
Date: September 5, 2025	By:	/s/ Dror Ben-Asher
​	Name:	Dror Ben-Asher	​
​	Title:	Chief Executive Officer	​

​

​

​

​

2

FAQ

What is the purpose of RedHill Biopharma (RDHL) filing this Form 6-K/A?

RedHill Biopharma filed this Form 6-K/A solely to add Exhibit 99.3, its management discussion and analysis of first half 2025 financial results. The company confirms all other information from the original Form 6-K furnished on September 5, 2025 remains unchanged.

What exhibits are included in RedHill Biopharma’s amended Form 6-K for September 2025?

The amended Form 6-K includes three exhibits: a press release on first half 2025 financial results and operational highlights (Exhibit 99.1), condensed consolidated interim unaudited financial information as of June 30, 2025 (Exhibit 99.2), and the management discussion and analysis for the same period (Exhibit 99.3).

What was missing from RedHill Biopharma’s original September 5, 2025 Form 6-K?

The original Form 6-K inadvertently omitted Exhibit 99.3, containing management’s discussion and analysis of first half 2025 financial results. The amendment corrects this omission by adding that exhibit, while affirming that all other content from the original filing remains the same.

How does this Form 6-K/A affect RedHill Biopharma’s existing registration statements?

The Form 6-K/A is incorporated by reference into RedHill Biopharma’s various Form S-8 and Form F-3 registration statements listed in the document. This means the information in the amended Form 6-K, including Exhibit 99.3, becomes part of those registration statements.

Does RedHill Biopharma’s Form 6-K/A change its first half 2025 financial results?

The amendment does not change RedHill Biopharma’s first half 2025 financial results. It only adds the management discussion and analysis as Exhibit 99.3. The press release and condensed interim unaudited financial information originally furnished remain unchanged, according to the company.

Who signed RedHill Biopharma’s amended Form 6-K for September 2025?

The amended Form 6-K was signed on behalf of RedHill Biopharma by Dror Ben-Asher, the company’s Chief Executive Officer. His signature confirms the filing under the requirements of the Securities Exchange Act of 1934 for foreign private issuers.